AbbVie Inc. Files 8-K on Financials and Senior Notes

Ticker: ABBV · Form: 8-K · Filed: 2024-07-03T00:00:00.000Z

Sentiment: neutral

Topics: financial-condition, debt-filing, senior-notes

Related Tickers: ABBV

TL;DR

AbbVie dropped an 8-K on July 3rd detailing its financial condition and various senior notes due between 2027 and 2031.

AI Summary

On July 3, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior notes, such as the 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes due 2028, 2.125% Senior Notes due 2029, and 1.250% Senior Notes due 2031, all listed on the NYSE.

Why It Matters

This filing provides investors with updated information on AbbVie's financial instruments, specifically its outstanding senior notes, which are crucial for understanding the company's debt structure and financial obligations.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of financial information and does not indicate any immediate or significant risks to the company.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by AbbVie Inc.?

The primary purpose of this 8-K filing is to report on AbbVie Inc.'s results of operations and financial condition, as well as to include financial statements and exhibits.

On what date was this 8-K report filed?

This 8-K report was filed on July 3, 2024.

Which specific senior notes are mentioned in the filing?

The filing mentions the 0.750% Senior Notes due 2027, 2.125% Senior Notes due 2028, 2.625% Senior Notes due 2028, 2.125% Senior Notes due 2029, and 1.250% Senior Notes due 2031.

Where are these senior notes listed?

These senior notes are listed on the NYSE (New York Stock Exchange).

What is AbbVie Inc.'s Standard Industrial Classification (SIC) code?

AbbVie Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.

From the Filing

0001551152-24-000024.txt : 20240703 0001551152-24-000024.hdr.sgml : 20240703 20240703140748 ACCESSION NUMBER: 0001551152-24-000024 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240703 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 241099482 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20240703.htm 8-K abbv-20240703 0001551152 false 0001551152 2024-07-03 2024-07-03 0001551152 us-gaap:CommonStockMember exch:XCHI 2024-07-03 2024-07-03 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-07-03 2024-07-03 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2024-07-03 2024-07-03 0001551152 abbv:Sec2.125SeniorNotesdue2028Member exch:XNYS 2024-07-03 2024-07-03 0001551152 exch:XNYS abbv:Sec2625SeniorNotesDue2028Member 2024-07-03 2024-07-03 0001551152 exch:XNYS abbv:Sec2125SeniorNotesDue2029Member 2024-07-03 2024-07-03 0001551152 exch:XNYS abbv:Sec1.250SeniorNotesdue2031Member 2024-07-03 2024-07-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): July 3, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange Chicago Stock Exchange 0.750% Senior Notes due 2027 ABBV27 New York Stock Exchange 2.125% Senior Notes due 2028 ABBV28 New York Stock Exchange 2.625% Senior Not

View on Read The Filing